Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 23 studies | 32% ± 13% | |
smooth muscle cell | 21 studies | 32% ± 14% | |
endothelial cell | 12 studies | 27% ± 12% | |
retinal rod cell | 8 studies | 35% ± 14% | |
capillary endothelial cell | 6 studies | 20% ± 4% | |
endothelial cell of artery | 5 studies | 21% ± 8% | |
cardiac muscle cell | 5 studies | 26% ± 5% | |
non-classical monocyte | 4 studies | 28% ± 9% | |
retinal cone cell | 4 studies | 52% ± 20% | |
pancreatic A cell | 3 studies | 40% ± 18% | |
retinal bipolar neuron | 3 studies | 35% ± 8% | |
rod bipolar cell | 3 studies | 29% ± 5% | |
endothelial cell of vascular tree | 3 studies | 21% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
eye | 6 studies | 30% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 96% | 6257.29 | 235 / 245 | 100% | 149.73 | 500 / 502 |
lung | 97% | 5067.65 | 563 / 578 | 96% | 70.24 | 1114 / 1155 |
breast | 94% | 3762.11 | 430 / 459 | 96% | 43.01 | 1068 / 1118 |
stomach | 97% | 6158.57 | 348 / 359 | 92% | 65.50 | 262 / 286 |
thymus | 85% | 3091.09 | 556 / 653 | 99% | 59.75 | 598 / 605 |
uterus | 97% | 6767.06 | 165 / 170 | 85% | 51.22 | 391 / 459 |
pancreas | 84% | 5337.66 | 276 / 328 | 98% | 55.07 | 174 / 178 |
intestine | 80% | 3959.63 | 771 / 966 | 92% | 70.72 | 484 / 527 |
kidney | 80% | 3428.17 | 71 / 89 | 89% | 50.80 | 806 / 901 |
ovary | 69% | 3414.26 | 124 / 180 | 99% | 92.47 | 427 / 430 |
bladder | 71% | 3057.71 | 15 / 21 | 84% | 44.57 | 421 / 504 |
esophagus | 69% | 5826.83 | 994 / 1445 | 77% | 27.45 | 141 / 183 |
brain | 38% | 917.43 | 995 / 2642 | 97% | 46.59 | 686 / 705 |
skin | 34% | 846.43 | 619 / 1809 | 90% | 61.48 | 426 / 472 |
adrenal gland | 28% | 627.90 | 73 / 258 | 89% | 44.49 | 205 / 230 |
eye | 0% | 0 | 0 / 0 | 100% | 257.55 | 80 / 80 |
heart | 100% | 21863.08 | 861 / 861 | 0% | 0 | 0 / 0 |
muscle | 100% | 27594.61 | 803 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 9968.59 | 1327 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 4424.32 | 239 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 41.41 | 42 / 45 |
adipose | 89% | 3564.65 | 1070 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 44.52 | 24 / 29 |
liver | 3% | 47.55 | 6 / 226 | 58% | 29.56 | 235 / 406 |
peripheral blood | 46% | 1989.01 | 427 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1900746 | Biological process | regulation of vascular endothelial growth factor signaling pathway |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0043117 | Biological process | positive regulation of vascular permeability |
GO_1904951 | Biological process | positive regulation of establishment of protein localization |
GO_0043542 | Biological process | endothelial cell migration |
GO_0007219 | Biological process | Notch signaling pathway |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0005769 | Cellular component | early endosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004727 | Molecular function | prenylated protein tyrosine phosphatase activity |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PTP4A3 |
Protein name | Protein tyrosine phosphatase 4A3 (Protein tyrosine phosphatase type IVA 3) Protein tyrosine phosphatase type IVA 3 (EC 3.1.3.48) (PRL-R) (Protein-tyrosine phosphatase 4a3) (Protein-tyrosine phosphatase of regenerating liver 3) (PRL-3) Protein tyrosine phosphatase 4A3 |
Synonyms | PRL3 |
Description | FUNCTION: Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. May be involved in the progression of cardiac hypertrophy by inhibiting intracellular calcium mobilization in response to angiotensin II. . |
Accessions | ENST00000524028.1 E5RFQ4 ENST00000523147.5 ENST00000707616.1 [O75365-1] ENST00000520105.5 [O75365-2] ENST00000349124.3 [O75365-1] ENST00000707614.1 [O75365-2] ENST00000521578.6 [O75365-1] O75365 ENST00000622569.3 [O75365-1] ENST00000633518.1 [O75365-1] ENST00000680615.1 [O75365-1] ENST00000707617.1 [O75365-1] ENST00000329397.6 [O75365-1] E5RGR3 ENST00000681443.1 [O75365-2] ENST00000707619.1 [O75365-1] ENST00000633621.1 [O75365-2] ENST00000707620.1 [O75365-2] ENST00000633262.1 ENST00000614325.2 [O75365-2] ENST00000707618.1 [O75365-1] |